Lowest Price Guaranteed
Pages
303
Last Updated
August 2026
View Count
5697
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Market Segmentations
1.4. Key Questions Answered
1.5. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Key Milestones and Historical Trends
6.2.1. Discovery of RNAi
6.2.2. RNAi Therapy Development Efforts
6.3. Mechanism of RNAi
6.3.1. Components of RNAi
6.3.2. Cellular Mechanism
6.4. Types of RNAi Molecules
6.4.1. siRNA
6.4.2. miRNA
6.4.3. shRNA
6.5. Applications of RNAi
6.5.1. Functional Genomics
6.5.2. Therapeutics
6.5.3. Biotechnology
6.5.4. Genome-scale Screening
6.6. Advantages and Disadvantages of RNAi
6.6.1. Advantages of RNAi
6.6.2. Disadvantages of RNAi
6.6.3. Case Study: Concerns Discussed During Regulatory Submissions in Clinic
6.7. Future Perspectives
7. MARKET OVERVIEW
7.1. Chapter Overview
7.2. RNAi Technology Platforms and Delivery Systems
7.2.1. Analysis by Purpose of Technology
7.2.2. Analysis by Type of Molecule Delivered
7.2.3. Analysis by Type of Cell / Tissue Targeted
7.2.4. Analysis by Target Gene
7.3. RNAi Technology Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters (Region-wise)
7.3.4. Analysis by Location of Headquarters (Country-wise)
8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions / Key Parameters
8.3. Methodology
8.4. Technology Competitiveness Analysis: RNAi Therapeutics Technologies
8.4.1. Technology Competitiveness Analysis: Drug Delivery Technologies
8.4.2. Technology Competitiveness Analysis: Drug Discovery / Development Technologies
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions / Key Parameters
9.3. Methodology
9.4. Company Competitiveness Analysis: RNAi Therapeutics Developers
9.5. Developers based in North America
9.6. Developers based in Europe
9.7. Developers based in Asia-Pacific
10. COMPANY PROFILES
10.1. Chapter Overview
10.2. Alnylam Pharmaceuticals*
10.2.1. Company Overview
10.2.2. RNAi Technology Portfolio
10.2.3. Management Team
10.2.4. Key Initiatives
* Similar details are presented for other RNAi technology developers mentioned below (based on information in the public domain)
10.3. Arrowhead Pharmaceuticals
10.4. Dicerna Pharmaceuticals
10.5. Merck
10.6. Revvity
10.7. Silence Therapeutics
10.8. Sirnaomics
10.9. Thermo Fisher Scientific
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. RNAi Technology: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Patent Type and Publication Year
11.3.3. Analysis by CPC Code
11.3.4. Analysis by Type of Applicant
11.3.5. Analysis by Geography
11.3.6. Emerging Focus Areas
11.3.7. Leading Players: Analysis by Number of Patents
11.3.8. Patent Benchmarking Analysis
11.3.9. Patent Valuation Analysis
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. RNAi Technology: Recent Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of RNAi Molecule
12.3.4. Analysis by Scale of Partnership
12.3.5. Analysis by Therapeutic Area
12.3.6. Most Active Players: Analysis by Number of Partnerships
12.3.7. Regional Analysis
12.3.7.1. Country-wise Distribution
12.3.7.2. Intercontinental and Intracontinental Deals
13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. RNAi Technology: Funding and Investment Analysis
13.3.1. Analysis by Cumulative Funding Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Analysis by Year and Type of Funding
13.3.5. Analysis of Amount Invested Across Different Types of RNAi Molecules
13.3.6. Regional Analysis by Amount Invested
13.3.7. Most Active Players
13.3.8. Key Investors
13.4. Concluding Remarks
14. GLOBAL RNAi TECHNOLOGY MARKET
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Global RNAi Technology Market, Forecasted Estimates (till 2035)
14.4. Roots Analysis Perspective on Market Growth
14.5. Scenario Analysis
14.5.1. Conservative Scenario
14.5.2. Optimistic Scenario
14.6. Key Market Segmentations
15. RNAi TECHNOLOGY MARKET, BY TYPE OF MOLECULE
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. RNAi Technology Market: Distribution by Type of Molecule
15.3.1. RNAi Technology Market for miRNA, Forecasted Estimates (till 2035)
15.3.2. RNAi Technology Market for shRNA, Forecasted Estimates (till 2035)
15.3.3. RNAi Technology Market for siRNA, Forecasted Estimates (till 2035)
15.3.4. RNAi Technology Market for Other RNA Molecules, Forecasted Estimates (till 2035)
15.4. Data Triangulation and Validation
16. RNAi TECHNOLOGY MARKET, BY DELIVERY TECHNOLOGY
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. RNAi Technology Market: Distribution by Delivery Technology
16.3.1. RNAi Technology Market for Lipid Nanoparticles, Forecasted Estimates (till 2035)
16.3.2. RNAi Technology Market for Polymer and Conjugate Systems, Forecasted Estimates (till 2035)
16.3.3. RNAi Technology Market for Emerging Nanomaterials, Forecasted Estimates (till 2035)
16.3.4. RNAi Technology Market for Viral Vectors, Forecasted Estimates (till 2035)
16.4. Data Triangulation and Validation
17. RNAi TECHNOLOGY MARKET, BY APPLICATION AREA
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. RNAi Technology Market: Distribution by Application Area
17.3.1. RNAi Technology Market for Agriculture, Forecasted Estimates (till 2035)
17.3.2. RNAi Technology Market for Diagnostics, Forecasted Estimates (till 2035)
17.3.3. RNAi Technology Market for Drug Discovery and Screening, Forecasted Estimates (till 2035)
17.3.4. RNAi Technology Market for Therapeutics, Forecasted Estimates (till 2035)
17.3.5. RNAi Technology Market for Other Application Areas, Forecasted Estimates (till 2035)
17.4. Data Triangulation and Validation
18. RNAi TECHNOLOGY MARKET, BY END USER
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. RNAi Technology Market: Distribution by End User
18.3.1. RNAi Technology Market for Pharmaceutical and Biotechnology Companies, Forecasted Estimates (till 2035)
18.3.2. RNAi Technology Market for Academic and Research Institutes, Forecasted Estimates (till 2035)
18.3.3. RNAi Technology Market for Contract Development and Manufacturing Organizations, Forecasted Estimates (till 2035)
18.3.4. RNAi Technology Market for Diagnostic Laboratories, Forecasted Estimates (till 2035)
18.3.5. RNAi Technology Market for Other End Users, Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation
19. RNAi TECHNOLOGY MARKET, BY GEOGRAPHICAL REGIONS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. RNAi Technology Market: Distribution by Geographical Regions
19.3.1. RNAi Technology Market in North America: Forecasted Estimates (till 2035)
19.3.2. RNAi Technology Market in Europe: Forecasted Estimates (till 2035)
19.3.3. RNAi Technology Market in Asia-Pacific: Forecasted Estimates (till 2035)
19.3.4. RNAi Technology Market in Middle East and North Africa: Forecasted Estimates (till 2035)
19.3.5. RNAi Technology Market in Latin America: Forecasted Estimates (till 2035)
19.4. Market Dynamics Assessment
19.4.1. Penetration-Growth (P-G) Matrix
19.5. Data Triangulation and Validation
20. SWOT ANALYSIS
20.1. Chapter Overview
20.2. Strengths
20.3. Weaknesses
20.4. Opportunities
20.5. Threats
20.6. Comparison of SWOT Factors
20.6.1. Concluding Remarks
21. EXECUTIVE INSIGHTS
21.1. Chapter Overview
21.2. Company A
21.2.1. Company Snapshot
21.2.2. Interview Transcript: Founder and Chief Executive Officer
21.3. Company B
21.3.1. Company Snapshot
21.3.2. Interview Transcript: President and Chief Executive Officer
21.4. Company C
21.4.1. Company Snapshot
21.4.2. Interview Transcript: President and Chief Executive Officer
21.5. Company D
21.5.1. Company Snapshot
21.5.2. Interview Transcript: Chief Executive Officer and Co-Founder
21.6. Company E
21.6.1. Company Snapshot
21.6.2. Interview Transcript: Chief Executive Officer
21.7. Company F
21.7.1. Company Snapshot
21.7.2. Interview Transcript: Senior Vice President, Head of International Region
21.8. Company G
21.8.1. Company Snapshot
21.8.2. Interview Transcript: Executive Vice President, Chief Commercial Officer
21.9. Company H
21.9.1. Company Snapshot
21.9.2. Interview Transcript: Chief Technology Officer and Head of US Operations
21.10. Company I
21.10.1. Company Snapshot
21.10.2. Interview Transcript: Former Chief Medical Officer
21.11. Company J
21.11.1. Company Snapshot
21.11.2. Interview Transcript: Head of Advanced Drug Delivery
22. CONCLUSION
23. APPENDIX 1: TABULATED DATA
24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS